Byetta Lawsuits Move Forward, With New Ruling Issued in Federal Incretin Mimetics Litigation, Bernstein Liebhard LLP Reports

Share Article

The Firm is evaluating Byetta lawsuits and other product liability claims that allege incretin mimetic diabetes drugs caused patients to develop pancreatic cancer, pancreatitis and thyroid cancer.

Free Case Review
“Our Firm has heard from numerous individuals who allegedly developed pancreatic cancer due to their use of Byetta and other incretin mimetics. We are closely monitoring the litigation involving these drugs.

Byetta lawsuits(http://www.byettalawsuit.com) and other product liability claims that allege incretin mimetic Type 2 diabetes medications caused patients to develop pancreatic cancer continue to move forward in U.S. courts, Bernstein Liebhard LLP reports. According to a ruling issued in the U.S. District Court, Southern District of California on September 10, 2014, plaintiffs have been denied a Motion to Compel discovery of defendants’ analysis of a causal association between the drugs and pancreatic cancer. (In Re: Incretins Products Liability, Sales and Marketing Litigation, MDL 2452)

Among other things, the plaintiffs’ motion had specifically challenged the sufficiency of defendants’ responses to certain interrogatories. However, U.S. District Judge Anthony Battaglia found that the responses were sufficient given the limited scope of discovery previously set by the Court.

“Our Firm has heard from numerous individuals who allegedly developed pancreatic cancer due to their use of Byetta and other incretin mimetics. We are closely monitoring the litigation involving these drugs,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is currently offering free Byetta lawsuit evaluations to patients who may have been harmed by this drug.

Byetta Lawsuit allegations
According to court documents, more than 480 lawsuits have been filed in the Southern District of California on behalf of individuals who allegedly developed pancreatitis due to their use of Byetta, Januvia or Victoza. All of the complaints allege that the drugs’ manufacturers failed to warn doctors and patients about their potentially harmful effects on the pancreas, as well as their alleged association with an increased risk of pancreatic cancer.

Court records indicate that the litigation surrounding incretin mimetics has been growing since March 2013, when the U.S. Food & Drug Administration (FDA) announced it was reviewing findings from an unpublished study that indicated their use could be associated with precancerous changes in the cells of the pancreas. Though the agency has been unable to conclude that such a link exists, its review is ongoing.

In addition to the claims pending in the federal proceeding, court documents show that a number of Byetta lawsuits involving similar allegations have been consolidated in a state-level litigation underway in California Superior Court. (In re: Byetta Cases, JCCP No. 4574) AstraZeneca, the manufacturer of the drug, also disclosed in July that it had so settled more than 80 claim involving the medication.*

Individuals who developed pancreatic cancer, pancreatitis or thyroid cancer, allegedly due to their use of Byetta or another incretin mimetic may be entitled to compensation for their injury-related damages. To learn more about filing a Byetta lawsuit, please visit Bernstein Liebhard LLP’s website. For a free legal review, please call 800-511-5092.

*http://www.astrazeneca.com/cs/Satellite?blobcol=urldata&blobheader=application%2Fpdf&blobheadername1=Content-Disposition&blobheadername2=MDT-Type&blobheadervalue1=inline%3B+filename%3DPress-release.pdf&blobheadervalue2=abinary%3B+charset%3DUTF-8&blobkey=id&blobtable=MungoBlobs&blobwhere=1285677813451&ssbinary=true, AstraZeneca PLC, July 31, 2014

Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
800-511-5092

ATTORNEY ADVERTISING. © 2014 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter

Contact Information:
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info(at)consumerinjurylawyers(dot)com
http://www.byettalawsuit.com
https://plus.google.com/115936073311125306742?rel=author

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Felecia L. Stern
Follow us on
Visit website